Iodine quantification with dual-energy CT: phantom study and preliminary experience with VX2 residual tumour in rabbits after radiofrequency ablation.

OBJECTIVE The purpose of our study was to validate iodine quantification in a phantom study with dual-source dual-energy CT (DECT) and to apply this technique to differentiate benign periablational reactive tissue from residual tumour in VX2 carcinoma in rabbits after radiofrequency ablation (RFA). METHODS We applied iodine quantification with DECT in a phantom and in VX2 carcinoma in rabbits after incomplete RFA to differentiate benign periablational reactive tissue from residual tumour and evaluated its efficacy in demonstrating response to therapeutic RFA. A series of tubes containing solutions of varying iodine concentration were scanned with DECT. The iodine concentration was calculated and compared with known true iodine concentration. Triple-phase contrast-enhanced DECT data on 24 rabbits with VX2 carcinoma were then assessed at Day 3 (n=6), 1 week (n=6), 2 weeks (n=6) and 3 weeks (n=6) after incomplete RFA independently by 2 readers. Dual-energy postprocessing was used to produce iodine-only images. Regions of interest were positioned on the iodine image over the lesion and, as a reference, over the aorta, to record iodine concentration in the lesion and in the aorta. The pathological specimens were sectioned in the same plane as DECT imaging, and the lesion iodine concentration and lesion-to-aorta iodine ratio of residual tumour and benign periablational reactive tissue were assessed. RESULTS There was excellent correlation between calculated and true iodine concentration (r=0.999, p<0.0001) in the phantom study. The lesion iodine concentration and lesion-to-aorta iodine ratio in residual tumour were significantly higher than in benign periablational reactive tissue in the 2-week group during the arterial phase (AP) (p<0.01) and in the 3-week group during both the AP (p<0.05) and the portal venous phase (p<0.05). There was no significant difference between them with respect to the lesion iodine concentration or lesion-to-aorta iodine ratio in the 3-day and 1-week groups. CONCLUSION Iodine quantification with DECT is accurate in a phantom study and can be used to differentiate benign periablational reactive tissue from residual tumour in VX2 carcinoma in rabbits after RFA. ADVANCES IN KNOWLEDGE Iodine quantification with DECT may help in differentiating benign periablational reactive tissue from residual tumour in VX2 carcinoma in rabbits after RFA.

[1]  J. H. Lim,et al.  Therapeutic response assessment of percutaneous radiofrequency ablation for hepatocellular carcinoma: utility of contrast-enhanced agent detection imaging. , 2005, European journal of radiology.

[2]  J. Debatin,et al.  Assessment of liver tissue after radiofrequency ablation: findings with different imaging procedures. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  Xiaodong Zhou,et al.  Transmission electron microscopy of VX2 liver tumors after high-intensity focused ultrasound ablation enhanced with SonoVue® , 2009, Advances in therapy.

[4]  S. Curley,et al.  Radio-frequency ablation of liver tumors: assessment of therapeutic response and complications. , 2001, Radiographics : a review publication of the Radiological Society of North America, Inc.

[5]  Bradford J Wood,et al.  Percutaneous tumor ablation with radiofrequency , 2002, Cancer.

[6]  M. Neeman,et al.  Stimulation of tumour angiogenesis by proximal wounds: spatial and temporal analysis by MRI. , 1998, British Journal of Cancer.

[7]  L Solbiati,et al.  Hepatic metastases: percutaneous radio-frequency ablation with cooled-tip electrodes. , 1997, Radiology.

[8]  M. Schwaiger,et al.  Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  Xinmei Liang,et al.  Evaluation of a rabbit rectal VX2 carcinoma model using computed tomography and magnetic resonance imaging. , 2009, World journal of gastroenterology.

[10]  M. Caraglia,et al.  Vascular endothelial growth factor monitoring in advanced hepatocellular carcinoma patients treated with radiofrequency ablation plus octreotide: a single center experience. , 2008, Oncology reports.

[11]  N. Avril.  18F-FDG PET after radiofrequency ablation: Is timing everything? , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  P. Petrow,et al.  Hepatic tumors treated with percutaneous radio-frequency ablation: CT and MR imaging follow-up. , 2002, Radiology.

[13]  J. Ellis,et al.  Aortic enhancement during abdominal CT angiography: correlation with test injections, flow rates, and patient demographics. , 1999, AJR. American journal of roentgenology.

[14]  Huiman X Barnhart,et al.  Dual-energy CT for characterization of adrenal nodules: initial experience. , 2010, AJR. American journal of roentgenology.

[15]  K Kubota,et al.  From tumor biology to clinical PET: A review of positron emission tomography (PET) in oncology , 2001, Annals of nuclear medicine.

[16]  Christianne Leidecker,et al.  Dual-energy CT in patients suspected of having renal masses: can virtual nonenhanced images replace true nonenhanced images? , 2009, Radiology.

[17]  B. Yeh,et al.  Pulmonary embolism detection with dual-energy CT: experimental study of dual-source CT in rabbits. , 2009, Radiology.

[18]  Thomas Flohr,et al.  Image Fusion in Dual Energy Computed Tomography: Effect on Contrast Enhancement, Signal-to-Noise Ratio and Image Quality in Computed Tomography Angiography , 2009, Investigative radiology.

[19]  K. Stierstorfer,et al.  Technical principles of dual source CT. , 2008, European journal of radiology.

[20]  W. Kwon,et al.  Percutaneous radiofrequency ablation of small hepatocellular carcinoma invisible on both ultrasonography and unenhanced CT: a preliminary study of combined treatment with transarterial chemoembolisation. , 2009, The British journal of radiology.

[21]  Andrew C Larson,et al.  Quantitative dual energy CT measurements in rabbit VX2 liver tumors: Comparison to perfusion CT measurements and histopathological findings. , 2012, European journal of radiology.

[22]  S Nahum Goldberg,et al.  Image-guided tumor ablation: standardization of terminology and reporting criteria. , 2005, Radiology.

[23]  D. Choi,et al.  Hepatocellular carcinoma treated with percutaneous radio-frequency ablation: evaluation with follow-up multiphase helical CT. , 2001, Radiology.

[24]  A. Butler,et al.  Spectroscopic (multi-energy) CT distinguishes iodine and barium contrast material in MICE , 2010, European Radiology.

[25]  J. Seo,et al.  Clinical utility of dual-energy CT in the evaluation of solitary pulmonary nodules: initial experience. , 2008, Radiology.

[26]  B. Choi,et al.  CT color mapping of the arterial enhancement fraction of VX2 carcinoma implanted in rabbit liver: comparison with perfusion CT. , 2011, AJR. American journal of roentgenology.

[27]  D. Hough,et al.  Dual-energy and dual-source CT: is there a role in the abdomen and pelvis? , 2009, Radiologic clinics of North America.

[28]  L. Zatz.  The effect of the kVp level on EMI values. Selective imaging of various materials with different kVp settings. , 1976, Radiology.

[29]  Shinpei Sato,et al.  Percutaneous radiofrequency ablation for hepatocellular carcinoma , 2005, Cancer.

[30]  A. Alavi,et al.  Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[31]  Thomas Henzler,et al.  Functional imaging of lung cancer using dual energy CT: how does iodine related attenuation correlate with standardized uptake value of 18FDG-PET-CT? , 2011, European Radiology.

[32]  M. Macari,et al.  Dual energy CT: preliminary observations and potential clinical applications in the abdomen , 2008, European Radiology.

[33]  G. Lu,et al.  Detection of pulmonary embolism using dual-energy computed tomography and correlation with cardiovascular measurements: a preliminary study , 2009, Acta radiologica.

[34]  F. Orsi,et al.  Role of [18F]FDG-PET/CT after radiofrequency ablation of liver metastases: preliminary results , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[35]  Ernst Klotz,et al.  Dual-Energy Computed Tomography to Assess Tumor Response to Hepatic Radiofrequency Ablation: Potential Diagnostic Value of Virtual Noncontrast Images and Iodine Maps , 2011, Investigative radiology.

[36]  Y. Hiasa,et al.  Modified technique for determining therapeutic response to radiofrequency ablation therapy for hepatocellular carcinoma using US-volume system. , 2009, Oncology reports.

[37]  Thomas Henzler,et al.  Contrast-Enhanced Dual-Energy CT of Gastrointestinal Stromal Tumors: Is Iodine-Related Attenuation a Potential Indicator of Tumor Response? , 2012, Investigative radiology.

[38]  M. Macari,et al.  Iodine quantification with dual-energy CT: phantom study and preliminary experience with renal masses. , 2011, AJR. American journal of roentgenology.

[39]  D. Lu,et al.  Creation of radiofrequency lesions in a porcine model: correlation with sonography, CT, and histopathology. , 2000, AJR. American journal of roentgenology.

[40]  D. Hough,et al.  Evaluation of non-linear blending in dual-energy computed tomography. , 2008, European journal of radiology.

[41]  Thomas J Vogl,et al.  Image-guided tumor ablation: proposal for standardization of terms and reporting criteria. , 2003, Radiology.